Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2018-03-30 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
2017年年度报告披露提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (347 characters) stating that the full 2017 Annual Report of the company will be published on March 31, 2018, on a specified website. It does not contain the actual report or financial data but only informs investors about the upcoming report release. According to the 'MENU VS MEAL' rule, such a brief notice about report availability is classified as a Report Publication Announcement (RPA).
2018-03-30 Chinese
关于福安药业集团宁波天衡制药有限公司2017年度业绩承诺实现情况的说明之审核报告
Audit Report / Information Classification · 95% confidence The document is an audit report issued by an accounting firm (北京永拓会计师事务所) on the performance commitment realization of 福安药业集团宁波天衡制药有限公司 for the year 2017. It includes the auditor's responsibilities, management's responsibilities, audit opinion, and detailed financial performance data related to the performance commitments. The document references compliance with Chinese securities regulations and accounting standards, and it contains substantive financial data and audit conclusions. It is not merely an announcement or a certification letter but a standalone audit report on a specific financial matter related to asset restructuring and performance commitments. Therefore, the document fits the category of an Audit Report / Information (AR). FY 2017
2018-03-30 Chinese
2017年度控股股东及其他关联方占用资金情况专项审核报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审核报告" (special audit report) concerning the 2017 year-end situation of funds occupied by controlling shareholders and related parties of 福安药业（集团）股份有限公司. It is issued by an accounting firm and references the 2017 audited financial statements, but it is not the full annual report or audit report itself. The document includes a summary table of fund occupation and a statement that it is intended for regulatory disclosure purposes only. The document length is short (1930 characters), and it is a specialized audit report related to a specific regulatory requirement about related party fund occupation. This fits the category of Audit Report / Information (AR), as it is a standalone audit-related report focusing on a specific issue, not the full annual report or a general regulatory filing. It is not a report publication announcement or a certification letter, but a substantive audit report on a specific topic. FY 2017
2018-03-30 Chinese
关于福安药业集团烟台只楚药业有限公司2017年度业绩承诺实现情况的说明
Audit Report / Information Classification · 95% confidence The document is a detailed explanation regarding the fulfillment of a 2017 performance commitment related to a major asset restructuring involving 福安药业集团烟台只楚药业有限公司. It references regulatory compliance with the China Securities Regulatory Commission, details the asset acquisition, share issuance, and performance compensation agreements. It includes audited financial results for 2017 and discusses whether performance targets were met and compensation obligations. The document is not a full annual report but a specific disclosure about the performance commitment related to a major asset reorganization. It is not a simple announcement or certification but a substantive report on the asset restructuring and related performance commitments. This fits the category of Audit Report / Information (AR), as it includes audit results and detailed accounting of the asset acquisition and performance commitments, but is not a full annual report (10-K). The document length is under 5,000 characters but contains substantive financial and audit information, so it is not a mere announcement (RPA) or regulatory filing (RNS). FY 2017
2018-03-30 Chinese
独立董事2017年度述职报告（黎明）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report for 2017" from a company. It details the independent director's attendance at board and shareholder meetings, opinions on various company matters during the year, committee duties, on-site investigations, and efforts to protect investor rights. The content is a formal report by an independent director summarizing their activities and oversight during the fiscal year 2017. It is not a full annual report (10-K), audit report, or earnings release, but rather a specific governance-related report by an independent director. This fits best under Board/Management Information (MANG), which includes announcements or reports related to board members and senior management activities. The document length is short (2028 characters) and contains substantive content, not just an announcement or certification, so it is not RPA or RNS. Therefore, the classification is MANG with high confidence.
2018-03-30 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from the company 福安药业（集团）股份有限公司 regarding a change in accounting policies. It details the reasons for the change, references specific accounting standards issued by the Ministry of Finance, and includes opinions from the board of directors, independent directors, and the supervisory board. The document does not contain actual financial statements or detailed financial data but rather explains the policy change and its expected impact. The length is relatively short (1842 characters), and it is clearly an announcement about a change in accounting policy rather than a full financial report or audit report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-03-30 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.